Earnings call transcript: Ardelyx tops growth goals in Q3 2026 as stock jumps
In Ardelyx's third quarter earnings call for 2026, the biotech company reported a 19% increase in revenue compared to the previous year, reaching $125.5 million. While this was below the $129.22 million forecast, investors still responded positively, with the company's shares jumping 9.57% in after-hours trading to $3.32. The main growth driver was the product IBSRELA, which generated $96.3 million in revenue, a 23% increase year-over-year.
XPHOZAH revenue grew 7% to $29.2 million. The net loss narrowed to $700,000 from $1 million a year earlier, indicating improved financial leverage. Shares rose in after-hours trading, suggesting investors focused on the strong demand for IBSRELA and Ardelyx's reaffirmed full-year guidance. Despite a modest revenue miss, Ardelyx's solid third quarter demonstrated both the growth and operating leverage of the business.
The company held a strong cash position of $285.3 million, which will support continued investment in its pipeline as it works toward profitability in 2027. Ardelyx reaffirmed its full-year 2026 guidance, emphasizing the long-term growth potential of its products and the strength of its financial position.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
